HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
HONG KONG, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK),...